Wade J Sexton
Overview
Explore the profile of Wade J Sexton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
167
Citations
2372
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Antonelli L, Heidenreich A, Bagrodia A, Amini A, Baky F, Branger N, et al.
BJU Int
. 2024 Dec;
PMID: 39662898
Objectives: To reassess the role of primary retroperitoneal lymph node dissection (RPLND) in patients with marker-negative non-seminomatous germ cell tumour (NSGCT) clinical stage (CS) 2a, to explore results in patients...
2.
Li R, Villa N, Yu X, Johnson J, Borjas G, Dhillon J, et al.
Nat Med
. 2024 Nov;
31(1):176-188.
PMID: 39521884
There is a critical unmet need for safe and efficacious neoadjuvant treatment for cisplatin-ineligible patients with muscle-invasive bladder cancer. Here we launched a phase 1b study using the combination of...
3.
Liveringhouse C, Sim A, Zhang J, Jain R, Naidu S, Linkowski L, et al.
Clin Genitourin Cancer
. 2024 Oct;
22(6):102222.
PMID: 39353214
Background: Neuroendocrine carcinoma of the bladder (NEC-bladder) is a rare disease with poor outcomes and variable treatment approaches. Materials And Methods: Patients with localized NEC-bladder treated with surgery or radiation...
4.
Chahine S, Alkhatib K, Arakelyan G, Buxton C, Giannarini G, Hamilton R, et al.
Eur Urol Focus
. 2024 Aug;
PMID: 39147634
Background And Objective: There are limited data on the prevalence and management of testicular germ cell tumor (TGCT) cases presenting with venous tumor thrombus (VTT). Our objectives were to describe...
5.
Lotan Y, Barocas D, Chang S, Daneshmand S, Konety B, Meeks J, et al.
Bladder Cancer
. 2024 Jul;
9(4):305-312.
PMID: 38994243
No abstract available.
6.
Chamie K, Chang S, Rosser C, Kramolowski E, Gonzalgo M, Sexton W, et al.
Future Oncol
. 2024 Jul;
20(31):2307-2317.
PMID: 38953850
What Is This Summary About?: This is a summary of two studies that looked at the safety and effectiveness of a potential new treatment, N-803 (Anktiva), in combination with a...
7.
Linscott J, Miyagi H, Murthy P, Yao S, Grass G, Vosoughi A, et al.
Curr Oncol Rep
. 2024 Jun;
26(8):945-958.
PMID: 38837106
Purpose Of Review: This review sought to define the emerging roles of urinary tumor DNA (utDNA) for diagnosis, monitoring, and treatment of bladder cancer. Building from early landmark studies the...
8.
Flaig T, Spiess P, Abern M, Agarwal N, Bangs R, Buyyounouski M, et al.
J Natl Compr Canc Netw
. 2024 May;
22(4):216-225.
PMID: 38754471
Bladder cancer, the sixth most common cancer in the United States, is most commonly of the urothelial carcinoma histologic subtype. The clinical spectrum of bladder cancer is divided into 3...
9.
Chamie K, Chang S, Kramolowsky E, Gonzalgo M, Agarwal P, Bassett J, et al.
NEJM Evid
. 2024 Feb;
2(1):EVIDoa2200167.
PMID: 38320011
BACKGROUND: Patients with Bacillus Calmette–Guérin (BCG)–unresponsive non–muscle-invasive bladder cancer (NMIBC) have limited treatment options. The immune cell–activating interleukin-15 (IL-15) superagonist Nogapendekin alfa inbakicept (NAI), also known as N-803, may act...
10.